Cortexyme, Inc. (NASDAQ:CRTX – Get Rating)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.95 and traded as high as $1.83. Cortexyme shares last traded at $1.67, with a volume of 280,805 shares traded. Cortexyme Stock Performance The firm has a market […]
Cortexyme, Inc. (NASDAQ:CRTX – Get Rating)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.94 and traded as high as $1.53. Cortexyme shares last traded at $1.51, with a volume of 377,530 shares trading hands. Cortexyme Stock Up […]
Cortexyme (NASDAQ:CRTX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The company’s drug candidate […]
Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Rating) have been given a consensus rating of “Hold” by the eight analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. […]
Cortexyme, Inc. , a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of. | May 20, 2022